CN Patent

CN101119732A — 避孕药物制剂

Assigned to Bayer Pharma AG · Expires 2008-02-06 · 18y expired

What this patent protects

本发明涉及一种药物组合物，其包含当给予所述组合物时相当于1.5mg或2.0mg日剂量单元的量的地诺孕素和当给予所述组合物时相当于0.015mg或0.020mg日剂量单元的量的炔雌醇以及一种或多种药学可接受的载体，其用于至少21个日剂量单元。本发明还涉及口服避孕药物制剂，其包含1.5mg的17α－氰甲基－17－β－羟雌－4，9－二烯－3－酮(地诺孕素)和0.015或0.020mg的17α－乙炔基雌二醇(炔雌醇)或者2.0mg的地诺孕素和0.015mg的炔雌醇以及一种或多种药学可接受的载体，其构成28天月经周期的至少21个日剂量单元。

USPTO Abstract

本发明涉及一种药物组合物，其包含当给予所述组合物时相当于1.5mg或2.0mg日剂量单元的量的地诺孕素和当给予所述组合物时相当于0.015mg或0.020mg日剂量单元的量的炔雌醇以及一种或多种药学可接受的载体，其用于至少21个日剂量单元。本发明还涉及口服避孕药物制剂，其包含1.5mg的17α－氰甲基－17－β－羟雌－4，9－二烯－3－酮(地诺孕素)和0.015或0.020mg的17α－乙炔基雌二醇(炔雌醇)或者2.0mg的地诺孕素和0.015mg的炔雌醇以及一种或多种药学可接受的载体，其构成28天月经周期的至少21个日剂量单元。

Drugs covered by this patent

Natazia (DIENOGEST) · Mochida Pharmaceutical Co., Ltd.

Patent Metadata

Patent number: CN101119732A
Jurisdiction: CN
Classification: —
Expires: 2008-02-06
Drug substance claim: No
Drug product claim: No
Assignee: Bayer Pharma AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.